Low daunomycin concentrations protect colorectal cancer cells from hypoxia-induced apoptosis by Lechanteur, Chantal et al.
SHORT REPORTS
Low daunomycin concentrations protect colorectal cancer cells from
hypoxia-induced apoptosis
Chantal Lechanteur1, Nathalie Jacobs2, Roland Greimers2, Vale´rie Benoıˆt1, Vale´rie Deregowski1,
Alain Chariot1, Marie-Paule Merville1 and Vincent Bours*,1
1Laboratory of Medical Chemistry and Human Genetics, Center for Biomedical Integrated Genoproteomics, University of Lie`ge,
Belgium; 2 Laboratory of Anatomopathology, Center for Biomedical Integrated Genoproteomics, University of Lie`ge, Belgium
Hypoxia, a common feature of solid tumors, is a direct
stress that triggers apoptosis in many cell types. Poor or
irregular tumor vascularization also leads to a decreased
drug diffusion and cancer cells distant from blood vessels
(hypoxic cells) are exposed to low drug concentrations. In
this report, we show that low daunomycin concentrations
protect HCT116 colorectal cancer cells from hypoxia-
induced apoptosis. While hypoxia induced p53 accumula-
tion without expression of its responsive genes (bax and
p21), daunomycin treatment restored p53 transactivation
activity and cell cycle progression. We also demonstrated
a role for Akt activation in daunomycin-induced protec-
tion through phosphorylation and inactivation of the Bcl-2
family proapoptotic factor Bad. Our data therefore
suggest that chemotherapy could possibly, because of
low concentrations in poorly vascularized tumors, protect
cancer cells from hypoxia-induced cytotoxicity.
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Hypoxic solid tumors have a poorer prognosis than
well-oxygenated tumors, independently of treatment.
There is experimental evidence that the tumor micro-
environment affects both the malignant progression of
transformed cells and their responsiveness to chemo-
and radiotherapy (Brown and Giaccia, 1998; Vaupel
et al., 2001). Hypoxia may inﬂuence tumor biology in
opposing ways: it is toxic as a stress; but on the other
hand, hypoxic solid tumors contain viable cells, which
are particularly resistant to treatment and contribute to
disease relapse. Indeed, hypoxia is rapidly toxic in most
cell types as it can induce necrosis or apoptosis in
normal or in transformed cells (Yamaguchi et al., 2001;
Zhu et al., 2002). Cell death is particularly prominent in
the zones farthest from the tumor vasculature, where
hypoxia stimulates apoptosis (Graeber et al., 1996).
Several studies showed that poor O2 supply resulted in
p53-dependent programmed cell death (Graeber et al.,
1994). However, hypoxia may also be involved in the
development of a more aggressive phenotype and
contribute to metastasis. In experimental tumors,
hypoxia can provide a selective pressure for the
expansion of oncogenically transformed cell populations
with a reduced apoptotic response to hypoxia as well as
to chemotherapeutic agents (Graeber et al., 1996; Kim
et al., 1997). The protective effect of hypoxia against
radio- or chemotherapy-induced cytotoxicity has been
extensively explored (Ogiso et al., 2000; Vaupel et al.,
2001; Achison and Hupp, 2003).
Moreover, poor vascularization impairs chemother-
apeutic compound delivery by constricted blood vessels
and hypoxic cancer cells distant from blood vessels are
exposed to low drug concentration. Therefore, we
investigated the effect of low daunomycin concentra-
tions on hypoxia-induced apoptosis in HCT116 color-
ectal adenocarcinoma cells.
HCT116 human colorectal adenocarcinoma cells were
tested for viability in severe hypoxia. Hypoxic cells were
grown in a conditioned atmosphere where O2 was
maintained below 0.1%. Cell viability experiment
revealed that only 14.2% of HCT116 hypoxic cells were
still alive after 72 h as compared to normoxic controls
(Figure 1a).
Surprisingly, cotreatment of these cells with very low
daunomycin concentrations protected them against
hypoxia-induced toxicity. Indeed, 81.2% of cells
cotreated with 0.01 mM of daunomycin were still alive
after 3 days of hypoxia (P¼ 0.0005). Similarly, follow-
ing 48 h of daunomycin and hypoxia, cells replated in
normoxia could grow again while cells exposed to
hypoxia alone died (data not shown). This ‘protective
effect’ is concentration dependent and was less pro-
nounced with higher daunomycin concentrations (68%
of hypoxic cell viability with 0.05 mM daunomycin; and
44.5% with 0.1 mM daunomycin). Indeed, daunomycin
intrinsic cytotoxicity at these higher concentrations
reduced HCT116 cell viability in normoxic conditions
(Figure 1a).
As hypoxia is a well-known inducer of apoptosis, cell
extracts from hypoxic cells were analysed for PARP and
caspase-3 cleavage and activation (Figure 1b; top and
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bottom panels, respectively). Caspase-3 activation and
PARP cleavage were observed after 48 or 72 h of
hypoxia (Figure 1b, top and bottom panels, lanes 8 and
9). However, hypoxic HCT116 cells did not undergo
apoptosis in the presence of daunomycin, (0.01 mM) as in
these conditions, we could not observe any caspase-3
activation or PARP cleavage (Figure 1b; top and
bottom panels, lanes 11 and 12).
Several groups have previously demonstrated that
multiple pathways can stabilize p53 in response to
different forms of stress (Ashcroft et al., 2000). p53
activation by DNA damage is followed by increased
synthesis of downstream effector proteins. Hypoxic
stress, like DNA damage, induces p53 protein accumu-
lation and p53-dependent apoptosis in transformed cells
(Koumenis et al., 2001), but several reports indicated
that hypoxia-induced p53 has lost its transactivation
potential and rather behaves as a transcriptional
repressor in tumor cells. To address p53 expression
and activity in our experimental model, nuclear and
total protein extracts were prepared after 24, 48, and
72 h of hypoxia or hypoxia plus daunomycin treatment,
and expressions of p53 and of two p53-responsive
proteins, p21 and Bax, were investigated by Western
blot analysis.
Although hypoxia induced a strong p53 accumulation
in HCT116 cells (Figure 2, top panel, compare lane 1
with lanes 5–7), we did not observe any p21 expression
in these conditions (Figure 2, second panel, compare
lane 1 with lanes 5–7). However, daunomycin treatment
(0.01 mM) of hypoxic HCT116 cells resulted in a shorter
and reduced p53 accumulation, suggesting a link
between the protective effect and p53 destabilization
(Figure 2, top panel, lanes 8–10).
Interestingly, we observed a slight increase of p21
expression in hypoxic cells cotreated with 0.01 mM of
daunomycin, thus indicating restoration of a p53
transcriptional activity (Figure 2, second panel, lanes
8–10). A similar observation was obtained with higher
daunomycin concentrations (0.05 mM) (data not shown).
Hypoxia also failed to induce the accumulation of the
Bax protein while daunomycin treatment did (Figure 2,
third panel from the top). Cotreatment of hypoxic cells
with daunomycin 0.01 mM (or 0.05 mM; data not shown)
resulted in Bax accumulation (Figure 2, third panel from
the top, lanes 8–9). These results thus suggest that
hypoxia induces the accumulation of a transcriptionally
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Figure 1 Low daunomycin concentrations protect HCT116
adenocarcinoma cells from hypoxia-induced apoptosis. (a)
HCT116 cells (ATCC CCL 247) were treated with increasing
daunomycin concentrations (0.01–0.5mM) and incubated in hypox-
ia (black columns) or normoxia (white columns) for 3 days. Cell
viability was assessed with the WST-1 test (Boehringer Mannheim,
Mannheim, Germany). Each value represents the mean of three
independent experiments as compared to normoxic controls
(100%). Hypoxia was achieved with the PROOX 110 oxygen
controller, which provides oxygen control from 0.1 to 99.9% inside
one insert culture chamber sitting in a CO2- and temperature-
controlled incubator. Tissue culture dishes were placed in the
semisealed culture chamber and severe hypoxia (o0.1% O2) was
achieved by injection of a N2 95%–CO2 5% mixture. The oxygen
tension in the chamber was measured by an O2 sensor and
maintained below 0.1% O2 by PROOX 110. (b) Daunomycin
inhibits hypoxia-induced PARP and caspase-3 cleavage in HCT116
cells. Cells were left untreated (Ctrl) or were treated with 0.01 mM of
daunomycin (Dauno, Rhoˆne Poulenc Rorer-Brussels) and incu-
bated in hypoxia or normoxia for the indicated times. Total cell
lysates were made by resuspending the cellular pellets in lysis buffer
(HEPES 25mM, NaCl 150mM, Triton 0.5%, Glycerol 10%, DTT
1mM, sodium orthovanadate 1mM, b-glycerophosphate 25mM,
sodium ﬂuorure 1mM, and protease inhibitors) and were analysed
by Western blotting with antibodies recognizing PARP (mouse
anti-poly(ADP-ribose)polymerase monoclonal antibody, Oncogene
Research Products) or caspase-3 (mouse anti-caspase-3 monoclonal
antibody, Alexis Biochemichals). Arrows indicate the full-length
(116 kDa) and cleaved (85 kDa) PARP as well as the full-length
(32 kDa) and activated (17 and 12 kDa) caspase-3
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Figure 2 p53, p21, and Bax expression in response to hypoxia and
daunomycin. HCT116 cells were left untreated (Ctrl) or were
treated with 0.01mM of daunomycin (Dauno) and incubated in
hypoxia or normoxia for the indicated times. Total cell lysates were
analysed by Western blotting for p53 (mouse anti-p53 monoclonal
antibody Ab2, Oncogene Science), p21 (mouse anti p21/WAF 1
Ab-1 monoclonal antibody, Oncogene Research Products), or Bax
(mouse anti-Bax monoclonal antibody, Oncogene Research Pro-
ducts) expression
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Since transition between apoptotic cell death and
proliferation in stress conditions is regulated at cell cycle
checkpoints, we determined whether enhanced p21
expression induced a cell cycle arrest that prevented
hypoxia-induced apoptosis. The cell cycle parameters
were thus monitored under hypoxic conditions in the
presence or absence of low daunomycin concentrations.
Hypoxia led to an increased number of cells in S phase
and ultimately to apoptosis (Figure 3a, third panel).
Simultaneous daunomycin treatment (0.01 mM) restored
cell cycle progression after a transient accumulation in
S phase (Figure 3a, fourth panel). These data indicate
that daunomycin releases cells from hypoxia-induced
S-phase arrest.
To investigate whether p21 expression was required
for the daunomycin-mediated protective effect, p21-
deﬁcient HCT116 cells (HCT116 p21/) were tested
for viability after 3 days of hypoxia in the presence or
absence of daunomycin (Figure 3b and c). HCT116
p21/ cells were sensitive to hypoxia-induced apop-
tosis and were protected, similarly to the wild-type cells,
by treatment with 0.01 mM of daunomycin (Figure 3c;
P¼ 0.003). p21 is effectively not expressed in HCT116
p21/ cells as demonstrated by Western blotting
(Figure 3b, top panel lanes 1–10). Therefore, p21 did
not play any major role in the daunomycin-induced
protective effect.
Hypoxia inﬂuences a variety of signal transduction
pathways, including MAP kinases (Erk, JNK, and p38)
and PI3K/Akt kinases. Akt is a serine–threonine kinase
involved in proliferative, metabolic, and apoptotic
pathways and is critical for cell survival (Datta et al.,
1999; Nicholson and Anderson, 2002). Activated
phospho-Akt (P-Akt) has been shown to protect normal
and tumoral cells against hypoxia and p53-induced
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Figure 3 Cell cycle distribution and p21 role in HCT116 cells hypoxia-induced apoptosis and daunomycin protection. (a) Cell cycle
distribution. HCT116 cells were left untreated or were treated with 0.01 mM of daunomycin (Dauno) and incubated in hypoxia (H) or
normoxia (N) for the indicated times. Cells were then stained with propidium iodide in the presence of RNAse A as recommended by
the manufacturer (Cycle Test Plus DNA reagent kit ; Becton Dickinson, European HQ, Erembodegem, Belgium). Cells were analysed
with a FACStar plus ﬂow sorter (Becton) with a 100-mW air-cooled argon laser (spinnaker 1161; Spectra Physics, Mountain View, CA,
USA) and the CellQuest software (Macintosh, Facstation; Becton Dickinson). DNA histograms were analysed by MODFIT LT ﬂow
cytometry modeling software (Verity software house, Topsham, ME, USA). A representative result out of three independent
experiments is shown (NI: noninterpretable). (b) HCT116 p21/ cells do not express p21. HCT116 p21/ cells, kindly provided by
Drs Yu and Vogelstein (John Hopkins University), were left untreated (Ctrl) or treated with 0.01mM of daunomycin (Dauno) and
incubated in hypoxia or normoxia for the indicated times (Ctrlþ : wild-type HCT116 þ daunomycin). Total cell lysates were analysed
by Western blotting for the expression of p21. (c) HCT116 p21/ cells in hypoxia. HCT116 p21/ cells were left untreated (Ctrl) or
treated with 0.01mM daunomycin (Dauno) and incubated in hypoxia (black columns) or normoxia (white columns) for 3 days. Cell
viability was assessed with the WST-1 test. Each value represents the mean of three independent experiments as compared to untreated
normoxic cells (100%)
Daunomycin inhibits hypoxia-induced apoptosis
C Lechanteur et al
1790
Oncogene
hypoxia did not induce Akt activity in HCT116 cells
(Figure 4a, top panel from the top, lanes 5–7). However,
when hypoxic cells were treated with low daunomycin
concentrations, we observed a progressive increase of
P-Akt level (Figure 4a, top panel, lanes 8–10), whereas
total Akt expression remained unchanged (Figure 4a,
bottom panel). Moreover, LY294002, an Akt speciﬁc
inhibitor, abolished both the Akt phosphorylation and
the daunomycin protective effect (Figure 4a ﬁrst panel,
lanes 11–13 and 14–16 and Figure 4c, bottom panel) in a
cell viability assay.
An important if not dominant mechanism for
phospho-Akt-induced protection comes from its ability
to block the activation of Bad-dependent cell death
pathway. Akt-induced Bad phosphorylation inactivates
Bad ability to form heterodimers with antiapoptotic Bcl-
2 proteins, a step thought to be prominent in Bad
proapoptotic effects (Datta et al., 1997; del Peso et al.,
1997).
Phospho-Bad analysis by Western blotting correlated
Akt and Bad phosphorylation. Indeed, while hypoxia
did not induce Bad phosphorylation in HCT116 cells,
we observed a progressive Bad phosphorylation when
hypoxic cells were treated with low daunomycin
concentration (Figure 4b, top panel, lanes 5–7). More-
over, cell treatment with LY 294002 abolished Bad
phosphorylation (Figure 4b, top panel, lanes 8–10 and
11–13), as previously described (Datta et al., 1997), thus
conﬁrming that Bad phosphorylation was Akt depen-
dent in our model.
Although hypoxia is toxic for most cell types,
numerous studies report that hypoxia induces tumor
cell drug resistance through various mechanisms (Sanna
and Rofstad, 1994; Teicher, 1994; Tomida and Tsuruo,
1999). Poor vascularization impairs chemotherapeutic
compound delivery and cancer cells distant from blood
vessels (hypoxic cells) are exposed to lower drug
concentration. However, little was known about the
effect of low drug concentrations on hypoxia-induced
apoptosis. In this study, we report that low concentra-
tions of daunomycin, a common anticancer agent,
inhibit hypoxia-induced apoptosis in HCT116 colorectal
adenocarcinoma cells. Hypoxia triggered p53 accumula-
tion without induction of its responsive genes, while
daunomycin-induced protection correlated with reduced
p53 and restored p21 expression.
Controversial results have been reported on p53
involvement in hypoxia-induced apoptosis. Achison
and Hupp (2003) paradoxically showed that p53 loss
sensitized HCT116 cells to hypoxia-induced cell death
and that hypoxia attenuated p53 activation by
5-ﬂuorouracile. Conversely, in our study, p53-acceler-
ated degradation seems to be linked to daunomycin
cytoprotection. Experimental differences may account
for these discording results. In Achison’s study, cells
were exposed to 1% of O2, while we lowered the oxygen
concentration to o 0.1% O2 reaching severe hypoxia.
Our results are in agreement with other studies. Indeed,
HCT116 p53/ cells have lost their ability to undergo
apoptosis under hypoxia (Yu et al., 2002), while
only severe hypoxia induces p53-dependent apoptosis
(Koumenis et al., 2001).
All these studies agree that hypoxia-induced p53 is
not transcriptionally active. Indeed, Koumenis et al.
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Figure 4 Akt-dependent Bad phosphorylation and daunomycin-induced protection against hypoxia-induced apoptosis. (a, b)
HCT116 cells were left untreated (Ctrl) or were treated with 0.01 mM of daunomycin (Dauno) and incubated in hypoxia or normoxia
for the indicated times, in the absence or presence of LY294002 (LY, Alexis Biochemicals, dissolved in DMSO). Total cell lysates were
analysed by Western blotting for the expression of Akt, phospho-Akt (a) (rabbit anti-Akt and anti-phospho-Akt (Ser 473) polyclonal
antibodies, Cell Signaling), Bad and phospho-Bad (b) (rabbit anti-Bad and anti-phospho-Bad polyclonal antibodies, Cell Signalling).
(c) HCT116 cells were treated with daunomycin (DN) and incubated in hypoxia or normoxia for 3 days. This treatment was performed
in the absence or presence of LY294002 (LY; 1, 2, or 5 mM). Cell viability was assessed with the WST-1 test. Each value represents the
mean of three independent experiments as compared to normoxic controls (100%)
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demonstrated that, in contrast to DNA damage,
hypoxia fails to induce endogenous downstream p53-
regulated mRNAs and proteins despite p53 accumula-
tion and our results showed that the expression of the
p53-responsive genes p21 and bax is not induced in
HCT116 hypoxic cells.
Despite a lower p53 expression, daunomycin
treatment restored bax and p21 induction under
hypoxia, suggesting a restoration of p53 transcriptional
activity in hypoxic cells as previously described with
doxorubicin, another topoisomerase II inhibitor (Kou-
menis et al., 2001). However, in the referred report,
doxorubicine induced apoptosis by itself and the
addition of doxorubicine prior to hypoxic treatment
generated a substantial increase in the apoptotic rates.
Indeed, these authors used cytotoxic doxorubicine
concentrations, while we worked with low nontoxic
concentrations.
Recent papers have focused on an antiapoptotic role
of p21 in several cellular models indicating that the
choice between growth arrest and apoptosis in HCT116
colorectal cancer cells can be modulated by p21
(Yu et al., 2003). However, in our study, p21 did not
have a major role in the daunomycin protective effect as
p21 disruption in HCT116 cells (HCT116 p21/) did
not modify cell response to hypoxia and daunomycin.
PI3K/Akt pathway seems implicated in the protective
effect observed in our experimental conditions. Bene-
ﬁcial effects of Akt activation against hypoxic or
ischemic insults have been described in cardiomyocytes
and astrocytes (Ruscher et al., 2002; Chao et al., 2003).
Although there can be little doubt that PKB/Akt
promotes cell survival, the mechanisms involved have
only recently begun to emerge. In addition to inﬂuencing
the transcription of pro- and antiapoptotic genes,
numerous studies indicate that PKB/Akt promotes
survival by directly phosphorylating key regulators of
the apoptotic cascade (Datta et al., 1999; Nicholson and
Anderson, 2002). Bad, a member of the Bcl-2 family,
which promotes apoptosis by binding to and antagoniz-
ing the action of the prosurvival members of the family
such as Bcl-2 or Bcl-Xl, can be phosphorylated and
inhibited by Akt. Indeed, S136 phosphorylation pro-
motes the sequestration of Bad by 14-3-3 proteins in the
cytosol, thus preventing Bad from interacting with Bcl-2
or Bcl-Xl (Datta et al., 1997; del Peso et al., 1997). The
biological importance of Bad phosphorylation on Ser
136 in promoting survival has been demonstrated after
several stress signals. For example, Hirai et al.
(2004) demonstrated that Bad phosphorylation by Akt
in brain slices prevented cytochrome c-associated
apoptosis after hypoxia. NF-kB could also be induced
by Akt activation. However, we do not have any
evidence that NF-kB plays a role in Akt-dependent
cytoprotective effect as this activity is preserved in
HCT116 cells stably expressing an NF-kB super-
repressor (data not shown).
Our data indicate that low daunomycin concentra-
tions induced Bax expression in hypoxic cells but
inhibited apoptosis. This observation is indeed surpris-
ing and different hypotheses could possibly explain
it. As mentioned, Akt-dependent Bad phosphorylation
promotes its sequestration in the cytosol. The induction
of apoptosis requires a positive ratio between proapop-
totic and antiapoptotic members of the Bcl-2 family.
Possibly, Bax increased expression is not sufﬁcient
to induce apoptosis in the absence of mitochondrial
Bad. Alternatively, Akt could induce the expression
of apoptosis inhibitors acting downstream of Bax.
Indeed, data suggesting that Akt may inﬂuence
post-mitochondrial events have been reported as
Akt was shown to inhibit the activation of caspase-3
and -9 by released cytochrome c through unidentiﬁed
cytosolic factors (Nicholson and Anderson, 2002).
Finally, it is not clear whether Bax is really involved
in hypoxia-induced apoptosis and Bax induction is not
sufﬁcient for p53-induced apoptosis (Sakamuro et al.,
1997).
To our knowledge, this is the ﬁrst study reporting that
daunomycin prevents hypoxia-induced apoptosis
through activation of survival pathways, thus indicating
a novel mechanism explaining that cancer cells can resist
to a natural cytotoxic stress. Moreover, some reports
indicate that other drugs such as traztuzumab, tamox-
ifen, or doxorubicin could also activate the PI3K/Akt
pathway leading to resistance to these drugs (Plo et al.,
1999; Clark et al., 2002) and possibly also, as suggested
by our data, to hypoxia-induced apoptosis. The ability
to tolerate hypoxia and withstand apoptosis may be
required for tumor progression. PKB/Akt, with its
critical role in cell survival, may have an important
function in adaptation to these adverse environmental
changes.
While it has been widely reported that cancer cell
hypoxia can lead to tumor resistance to chemotherapy
and radiotherapy, our data indicate that in some cancer
cells, the administration of a chemotherapy could favor
the resistance of poorly vacularized tumors to hypoxia.
Therefore, it is quite possible that chemotherapy could
promote the survival of hypoxia-exposed cancer cells
and thus select such cells, thereby facilitating subsequent
cancer relapse. If such data could be conﬁrmed in other
models, it would strongly support the administration of
oxygenation-boosting agents simultaneously with che-
motherapy. Alternatively, inhibition of the PI3K/Akt
pathway could prevent the cytoprotective effect of low
local drug concentrations as suggested by a gene therapy
study demonstrating that in vivo expression of PTEN in
a model of the human bladder suppresses tumor growth,
downregulates phosphorylated Akt, and increases
sensitivity to doxorubicin (Tanaka and Grossman,
2003).
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